Centre Hospitalier Universitaire De Nantes
- Address
- lock Available on a paid plan
Neoplasms and thoracic oncology
The Centre Hospitalier Universitaire De Nantes is conducting clinical research in cancer, with a strong focus on extensive stage small cell lung cancer. These studies are centered on evaluating new treatment strategies for patients with advanced lung disease, aiming to improve survival and strengthen first-line care.
- Study of extensive stage small cell lung cancer as a major thoracic malignancy
- Testing whether adding a new therapy can improve overall survival
- Comparing combination treatment with standard immunotherapy alone
This work reflects a focused effort at the Service Oncologie Thoracique to advance treatment options for aggressive lung cancer and better define which approaches may offer the greatest benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 8 therapeutic areas and 15 of 107 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 106 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Nantes
lock Showing 1 of 51 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 107 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 9 | Unknown | 2019-11-20 | 2026-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.